Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06532630 | Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies | unknown | Early Phase 1 | 9 | Shanghai First Song Biotechnology Co., LTDINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06828341 | A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression | unknown | Early Phase 1 | 3 | JIANG LONGWEIOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05501899 | Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 20 | Children's Hospital of Orange CountyOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03537482 | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | unknown | Early Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 19, 2024 | clinicaltrials |
| NCT03244176 | Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study(AvR-CHOP) | unknown | Early Phase 1 | 28 | Austin HealthOTHER_GOV | 1 | Jul 30, 2024 | clinicaltrials |
| NCT05707325 | Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies(Reboot-101) | unknown | Early Phase 1 | 30 | Westlake TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05543954 | 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients | unknown | Early Phase 1 | 60 | Peking Union Medical College HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06428708 | [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma | unknown | Early Phase 1 | 30 | Western UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06462495 | Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis | unknown | Early Phase 1 | 30 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06462508 | Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis | unknown | Early Phase 1 | 30 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06455722 | [68Ga]Ga-P15-041 PET/CT in Variety of Bone Tumors | unknown | Early Phase 1 | 30 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06436885 | An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer | unknown | Early Phase 1 | 39 | Henan Cancer HospitalOTHER_GOV | 1 | May 31, 2024 | clinicaltrials |
| NCT06437496 | 68Ga-AAZTA-093 PET/CT: First-in-human Study | unknown | Early Phase 1 | 30 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06412952 | 68Ga-NOTA-RM26 PET/CT in Glioma Patients | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06393335 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | unknown | Early Phase 1 | 36 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06379451 | An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma | unknown | Early Phase 1 | 9 | Changzhou No.2 People's HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT05359146 | Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)(Beta plus) | unknown | Early Phase 1 | 16 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06361264 | Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide | unknown | Early Phase 1 | 20 | KARANAHANOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06347198 | Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer | unknown | Early Phase 1 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05043701 | Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma(ISM-GBM) | unknown | Early Phase 1 | 15 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06106152 | WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody | unknown | Early Phase 1 | 20 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02619448 | Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC | unknown | Early Phase 1 | 12 | State University of New York - Upstate Medical UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT03407859 | Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL | unknown | Early Phase 1 | 100 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04173988 | Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 6 | Children's Hospital of Fudan UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06097793 | KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial | unknown | Early Phase 1 | 12 | Kousai Bio Co., Ltd.OTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06224049 | Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T(GI-hNeoT-01) | unknown | Early Phase 1 | 6 | BGI, ChinaOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06277011 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05840107 | Study of FasT CAR-T GC012F Injection NDMM Patients | unknown | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06224738 | Human HER2-targeted Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal Metastases | unknown | Early Phase 1 | 9 | First People's Hospital of HangzhouOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06217848 | The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study | unknown | Early Phase 1 | 50 | Seoul National University HospitalOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06194630 | Application of 68Ga-labeled ACE2 Targeting Probe PET/CT Imaging in Tracing ACE2 Expression and Diagnosis of Lung Cancer | unknown | Early Phase 1 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05070156 | B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma | unknown | Early Phase 1 | 3 | Tongji UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06171282 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors | unknown | Early Phase 1 | 9 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT05747157 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06117878 | Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma | unknown | Early Phase 1 | 12 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06114173 | Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma | unknown | Early Phase 1 | 15 | Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06098898 | Safety and Efficacy of NK510 to Treat Gastric Cancer | unknown | Early Phase 1 | 9 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04074564 | MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma | unknown | Early Phase 1 | 60 | HRYZ Biotech Co.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06086327 | Application of 68Ga-Pentixafor PET/CT for Thymoma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06054984 | TCR-T Cells in the Treatment of Advanced Pancreatic Cancer(GB3010-02) | unknown | Early Phase 1 | 18 | Ruijin HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06067581 | the Safety and Efficacy of SENL103 Autologous T Cell Injection | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT06060964 | Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management(Breathe Easier) | unknown | Early Phase 1 | 24 | University of South CarolinaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT06050239 | Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer | unknown | Early Phase 1 | 10 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04831541 | 68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer | unknown | Early Phase 1 | 600 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04897542 | Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors | unknown | Early Phase 1 | 100 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT05932511 | Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer | unknown | Early Phase 1 | 15 | Center for Biomedical Research, Inc.INDUSTRY | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05673447 | The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma | unknown | Early Phase 1 | 12 | Changhai HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05802693 | A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma | unknown | Early Phase 1 | 22 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Aug 25, 2023 | clinicaltrials |
| NCT05979792 | Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma | unknown | Early Phase 1 | 35 | Zhao WeiliOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05648955 | Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment(ALLIES) | unknown | Early Phase 1 | 118 | Nutricia ResearchINDUSTRY | 1 | Jul 28, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 28, 2025source: clinicaltrials